Skip to main content
Top
Published in: Medical Oncology 2/2013

01-06-2013 | Original Paper

High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan

Authors: Jen-Hao Chen, Kun-Tu Yeh, Yu-Min Yang, Jan-Gowth Chang, Huey-Er Lee, Shih-Ya Hung

Published in: Medical Oncology | Issue 2/2013

Login to get access

Abstract

Since 2008, oral squamous cell carcinoma (OSCC) has climbed to the fourth place in cancer mortality in the male population of Taiwan. Epigenetic regulations including DNA methylation and histone modification control gene expression and play important roles during cancer progression. Since the relationship between histone modification and prognosis of OSCC is inconclusive, we collected 215 formalin-fixed and paraffin-embedded tissues from male patients having OSCC and surveyed them by tissue microarray-based immunohistochemical staining. The association between five histone modification-related genes, clinicopathological parameters, and prognosis of OSCC was examined. From tissue microarray immunohistochemistry staining results, we found that the nuclear staining intensity of ARK2 (Aurora kinase B-a serine/threonine-protein kinase of H3S10) was associated with poor clinical outcomes (≤3-year survival, p = 0.005). The cytosolic staining intensity of the ARK2 protein was associated with tumor stage (p = 0.006) and tumor size (T) of TNM staging system (p = 0.026). Cytoplasmic staining intensity of G9a (H3K9 methyltransferase) was associated with histological grade of differentiation (p = 0.026). EZH2 (H3K27 methyltransferase) and SUV39H1 (H3K9 methyltransferase) overexpressions in nuclei were, respectively, associated with lymph node metastasis (N, p = 0.016) and stage (p = 0.009). Our result suggests that overexpressions of histone modification-related proteins-ARK2, G9a, EZH2, and SUV39H1 but not SUV39H2 are associated with prognosis of OSCC in the male population of Taiwan. These proteins, especially ARK2, may serve as effective prognostic factors and can also be used as biomarkers for predicting various clinical outcomes of OSCCs in the Taiwanese population.
Literature
2.
go back to reference Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med. 1995;24(10):450–3.PubMedCrossRef Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med. 1995;24(10):450–3.PubMedCrossRef
5.
go back to reference Pugliano FA, Piccirillo JF, Zequeira MR, Fredrickson JM, Perez CA, Simpson JR. Clinical-severity staging system for oral cavity cancer: five-year survival rates. Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck. Surgery. 1999;120(1):38–45. Pugliano FA, Piccirillo JF, Zequeira MR, Fredrickson JM, Perez CA, Simpson JR. Clinical-severity staging system for oral cavity cancer: five-year survival rates. Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck. Surgery. 1999;120(1):38–45.
6.
go back to reference Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck Surg. 1984;6(5):938–47.PubMedCrossRef Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck Surg. 1984;6(5):938–47.PubMedCrossRef
7.
go back to reference Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999;98(3):285–94.PubMedCrossRef Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999;98(3):285–94.PubMedCrossRef
9.
10.
11.
go back to reference Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol. 2006;29(1):117–24.PubMed Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol. 2006;29(1):117–24.PubMed
13.
go back to reference Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab. 2005;90(2):928–35. doi:10.1210/jc.2004-1518.PubMedCrossRef Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab. 2005;90(2):928–35. doi:10.​1210/​jc.​2004-1518.PubMedCrossRef
16.
go back to reference Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena BS, Shimamoto F, et al. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Archiv. 2007;450(3):297–302. doi:10.1007/s00428-006-0360-9.PubMedCrossRef Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena BS, Shimamoto F, et al. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Archiv. 2007;450(3):297–302. doi:10.​1007/​s00428-006-0360-9.PubMedCrossRef
17.
go back to reference Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell. 2003;12(6):1591–8.PubMedCrossRef Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell. 2003;12(6):1591–8.PubMedCrossRef
18.
go back to reference Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002;16(14):1779–91. doi:10.1101/gad.989402.PubMedCrossRef Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002;16(14):1779–91. doi:10.​1101/​gad.​989402.PubMedCrossRef
19.
go back to reference Simon JA, Tamkun JW. Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes. Curr Opin Genet Dev. 2002;12(2):210–8.PubMedCrossRef Simon JA, Tamkun JW. Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes. Curr Opin Genet Dev. 2002;12(2):210–8.PubMedCrossRef
21.
go back to reference Peters AH, O’Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001;107(3):323–37.PubMedCrossRef Peters AH, O’Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001;107(3):323–37.PubMedCrossRef
22.
go back to reference Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80(9):1803–4.PubMedCrossRef Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80(9):1803–4.PubMedCrossRef
25.
go back to reference Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z, Vourvachis M, et al. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1–T2 oral squamous cell carcinoma patients. Head Neck Oncol. 2010;2:9. doi:10.1186/1758-3284-2-9.PubMedCrossRef Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z, Vourvachis M, et al. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1–T2 oral squamous cell carcinoma patients. Head Neck Oncol. 2010;2:9. doi:10.​1186/​1758-3284-2-9.PubMedCrossRef
26.
go back to reference Kudo Y, Takata T, Ogawa I, Sato S, Nikai H. Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Rep. 1999;6(3):539–45.PubMed Kudo Y, Takata T, Ogawa I, Sato S, Nikai H. Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Rep. 1999;6(3):539–45.PubMed
27.
go back to reference Myoung H, Kim MJ, Lee JH, Ok YJ, Paeng JY, Yun PY. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg. 2006;35(11):1005–10. doi:10.1016/j.ijom.2006.07.016.PubMedCrossRef Myoung H, Kim MJ, Lee JH, Ok YJ, Paeng JY, Yun PY. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg. 2006;35(11):1005–10. doi:10.​1016/​j.​ijom.​2006.​07.​016.PubMedCrossRef
28.
go back to reference Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2’-deoxycytidine. Cancer Res. 2002;62(22):6456–61.PubMed Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2’-deoxycytidine. Cancer Res. 2002;62(22):6456–61.PubMed
29.
31.
go back to reference Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40(6):741–50. doi:10.1038/ng.159.PubMedCrossRef Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40(6):741–50. doi:10.​1038/​ng.​159.PubMedCrossRef
32.
go back to reference Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol. 2005;36(12):1281–8. doi:10.1016/j.humpath.2005.09.014.PubMedCrossRef Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol. 2005;36(12):1281–8. doi:10.​1016/​j.​humpath.​2005.​09.​014.PubMedCrossRef
33.
go back to reference Pannone G, Hindi SA, Santoro A, Sanguedolce F, Rubini C, Cincione RI, et al. Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma. Int J Immunopathol Pharmacol. 2011;24(1):79–88.PubMed Pannone G, Hindi SA, Santoro A, Sanguedolce F, Rubini C, Cincione RI, et al. Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma. Int J Immunopathol Pharmacol. 2011;24(1):79–88.PubMed
34.
36.
go back to reference Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9. doi:10.1038/nature01075.PubMedCrossRef Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9. doi:10.​1038/​nature01075.PubMedCrossRef
37.
go back to reference Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100(20):11606–11. doi:10.1073/pnas.1933744100.PubMedCrossRef Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100(20):11606–11. doi:10.​1073/​pnas.​1933744100.PubMedCrossRef
38.
go back to reference Cao W, Feng Z, Cui Z, Zhang C, Sun Z, Mao L, et al. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer. 2012;118(11):2858–71. doi:10.1002/cncr.26575.PubMedCrossRef Cao W, Feng Z, Cui Z, Zhang C, Sun Z, Mao L, et al. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer. 2012;118(11):2858–71. doi:10.​1002/​cncr.​26575.PubMedCrossRef
39.
go back to reference Cao W, Younis RH, Li J, Chen H, Xia R, Mao L, et al. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prevent Res. 2011;4(11):1816–24. doi:10.1158/1940-6207.CAPR-11-0130.CrossRef Cao W, Younis RH, Li J, Chen H, Xia R, Mao L, et al. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prevent Res. 2011;4(11):1816–24. doi:10.​1158/​1940-6207.​CAPR-11-0130.CrossRef
40.
go back to reference Vekony H, Raaphorst FM, Otte AP, van Lohuizen M, Leemans CR, van der Waal I, et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol. 2008;61(6):744–9. doi:10.1136/jcp.2007.054262.PubMedCrossRef Vekony H, Raaphorst FM, Otte AP, van Lohuizen M, Leemans CR, van der Waal I, et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol. 2008;61(6):744–9. doi:10.​1136/​jcp.​2007.​054262.PubMedCrossRef
42.
go back to reference Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436(7051):660–5. doi:10.1038/nature03841.PubMedCrossRef Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436(7051):660–5. doi:10.​1038/​nature03841.PubMedCrossRef
44.
go back to reference Patani N, Jiang WG, Newbold RF, Mokbel K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res. 2011;31(12):4115–25.PubMed Patani N, Jiang WG, Newbold RF, Mokbel K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res. 2011;31(12):4115–25.PubMed
Metadata
Title
High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan
Authors
Jen-Hao Chen
Kun-Tu Yeh
Yu-Min Yang
Jan-Gowth Chang
Huey-Er Lee
Shih-Ya Hung
Publication date
01-06-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0513-z

Other articles of this Issue 2/2013

Medical Oncology 2/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.